FACIAL INJECTABLES MARKET ANALYSIS

Facial Injectables Market, By Product Type (Dermal Fillers (Hyaluronic Acid Fillers, Collagen Fillers and Synthetic Fillers) and Anti-wrinkle Injections (Botulinum Toxin A and Poly-L-lactic acid (PLLA)), By Application (Wrinkle Reduction, Facelift, Lip Enhancement, and Others), By End User (Hospitals, Beauty Clinics, and Dermatology Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Dec 2019
Code : CMI1329
Pages :182
Formats :
Excel and PDF
Industry : Pharmaceutical

Facial Injectables MarketSize and Trends

The global facial injectables market was valued at US$ 5,088.5 million in 2019, and is expected to witness a CAGR of 14.9% over the forecast period (2019 – 2027).

Rising Demand for Facial Injectables to Enhance Aesthetic Beauty Is Expected To Drive Growth of The Global Facial Injectables Market.

Aesthetic procedure uses minimally invasive cosmetic procedures to improve the appearance. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS) in 2015, more than 20 million aesthetic procedures were performed globally. The demand for minimally invasive cosmetic procedures has led to an increase in demand for cosmetic products. In emerging economies, aesthetic medicine is gaining significant traction as people consider it as a part of a normal health treatment owing to the need to maintain a natural and healthy appearance.

Moreover, increasing promotional activities, rapidly developing healthcare infrastructure, and rising disposable income of the population are some of the factors that are expected to propel the facial injectables market growth. For instance, according to the American Society for Aesthetic Plastic Surgery (ASAPS), in 2016, people in the U.S. spent over US$ 15 billion on combined surgical and non-surgical aesthetic procedures, accounting for an 11% increase during 2015. Out of this, non-surgical procedures accounted for 44% of the total procedural spending.